Robert Gadimian Advises Effective New Natural Skin Cancer Treatment: BEC5

A novel topical natural treatment has been surfaced that has many advantages over the currently used skin cancer therapies, according to Robert Gadimian, owner of Rophe Pharma. ... For individuals with skin cancer, Robert Gadimian advises that BEC5 could be a very viable alternate to current cancer treatments especially considering its safety and efficacy.

Derived from an eggplant, this treatment is a topical cream that contains BEC5. BEC5 consists of the antineoplastic compounds solasodine rhamnosyl glycosides, solamargine and solasonine, which are derived from eggplant and is very effective for treating non-melanoma skin cancers. Advantages of treatment of these lesions with BEC5 compared with well-established surgical interventions and other therapies have been reported in the scientific literature [Reference 1-10].

Alternative to surgery or chemo

The majority of individuals that acquire skin cancers are typically exposed to conventional treatment that uses the cut (surgery), poison (chemotherapy) and burn (radiation) approach. Gadimian believes that a safe, effective and relatively inexpensive natural alternative to the standard model is badly needed.

Skin cancer rates rising

Skin cancer incidence is increasing at alarming rates. Its incidence is among the highest in the cancers types. The incidences of nonmelanoma skin cancers such as basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) have increased more than 300 percent since 1992. For malignant melanoma, increased rates of over 500 percent have been reported from 1975 to 2008.

The developments of new treatments have not caught up with the increased incidences of this disease. A variety of treatments are available with differing outcomes but the limitations and costs of current treatments for skin cancers pose many shortfalls and many patients afflicted with these diseases do not seek proper treatment, resulting in increased morbidity and mortality.

Risks of surgery

Basal Cell Carcinoma is a slow growing locally invasive malignant skin tumor which mainly affects Caucasians. Dermatologists, plastic surgeons, and radiotherapists jointly manage this disease which usually involves surgery. The risks of surgical intervention are well known.

Moreover, excision of basal cell carcinoma from the facial area often involves reconstructive surgery; which can be both time consuming and costly. Hence an alternative, safe and efficacious method of treatment of basal cell carcinoma that does not require physician or hospital attendance must be encouraged.

BEC5: A non-invasive and inexpensive treatment

The treatment time period with topical BEC5 to completely eliminate skin cancers varies from days to months depending on size and type of skin tumours. Large nonmelanoma skin cancers can successfully be treated with BEC5 and it may take several months of treatment to eliminate these large tumours [Reference 1-10].

Unlike established antimitotic drugs, BEC5 is not antimitotic in its actions. BEC5 induces apoptosis (planned self-destruction of cells) in cancer cells by up-regulating the expressions of external death receptors. BEC5 also triggers extrinsic and intrinsic apoptotic pathways in cancer cells [Reference 1-10].

BEC5 topical cream: safe and effective

Solamargine, the main component of BEC5, also kills cancer cells by oncosis. After interaction of solamargine with cancer cells, marked changes in cell shape and volume occur. The cells get blebs (protrusions) on the membrane, the mitochondria swell, the contents of the nuclei clump and the cells die. It has been proposed that apoptosis and oncosis share certain mechanisms and alterations within the cell before they die by bursting. At low concentrations, solamargine kills cancer cells by apoptosis and at higher doses, solamargine kills cancer cells by oncosis, and both types of cell death are induced by intermediate concentrations of solamargine. Thus, the beauty of BEC is that it penetrates and kills cancer cells but does not penetrate normal cells, so normal cells are untouched and unhurt while the cancer cells die.

It has recently been shown that, in addition to causing apoptosis in cancer cells, intralesion administration of BEC5 also stimulates lasting immunity against cancer. BEC5 has also shown in a clinical study done with 78 patients to cure actinic keratosis that can advance to squamous cell carcinoma, which in turn is associated with a risk of metastasis. In this study 92% of the patients had complete clearance after treatment and had 82% clearance after one year.

For individuals with skin cancer, Gadimian advises that BEC5 could be a very viable alternate to current cancer treatments especially considering its safety and efficacy.

  1. T. R. Chase, “Curaderm BEC5 for Skin Cancers, Is It? An Overview,” Journal Cancer Therapy, Vol. 2, No. 5, 2011, pp. 728-745. doi:10.4236/jct.2011.25099
  2. B. E. Cham, “Eggplant Wins War against Skin Cancer. Conquest on the Horizon for Internal Cancers?” in Preparation.
  3. B. E. Cham, “The Eggplant Cancer Cure. A Treatment for Skin Cancer and New Hope for Other Cancers from Nature’s Pharmacy,” Smart Publications, Petaluma, 2007, p. 122.
  4. B. E. Cham, “Solasodine Rhamnosyl Glycosides Specifically Bind Cancer Cell Receptors and Induce Apoptosis and Necrosis. Treatment for Skin Cancer and Hope for Internal Cancers,” Research Journal Biological Sciences, Vol. 2, No. 7, 2007, pp. 503-514.
  5. B. E. Cham, “Solasodine Rhamnosyl Glycosides in a Cream Formulation Is Effective for Treating Large and Troublesome Skin Cancers,” Research Journal Biological Sciences, Vol. 2, No. 7, 2007, pp. 749-761.
  6. B. E. Cham and T. R. Chase, “Solasodine Rhamnosyl Glycosides Cause Apoptosis in Cancer Cells, Do They also Prime the Immune System Resulting in Long Term Protection against Cancer?” Planta Medica, Vol. 78, 2012, pp. 349-353. doi:10.1055/s-0031-1298149   [Citation Time(s):2]
  7. B. E. Cham, “Monograph on the Compound BEC,” Drugs of the Future, Vol. 13, 1988, pp. 714-716.
  8. B. E. Cham, “Solasodine Glycosides as Anti-Cancer Agents: Pre-Clinical and Clinical Studies,” Asia Pacific Journal Pharmacology, Vol. 9, No. 2, 1994, pp. 113-118.
  9. B. E. Cham and B. Daunter, “Topical Treatment of Pre-Malignant and Malignant Skin Cancers with Curaderm,” Drugs of Today, Vol. 26, No. 3, 1990, pp. 55-58.
  10. B. E. Cham, B. Daunter and R. Evans, “Topical Treatment of Malignant and Premalignant Skin Cancers by Very Low Concentrations of a Standard Mixture of Solasodine Glycosides,” Cancer Letters, Vol. 59, No. 3, 1991, pp. 183-192. doi:10.1016/0304-3835(91)90140-D
  11. B. E. Cham and M. M. Meares, “Glycoalkaloids from Solanum sodomaeum L. Are Effective in the Treatment of Skin Cancers in Man,” Cancer Letters, Vol. 36, No. 2, 1987, pp. 111-118. doi:10.1016/0304-3835(87)90081-4
  12. S. Punjabi, I. Cook, P. Kersey, R. Marks, A. Finlay and G. Sharpe, “A Double Blind, Multi-Centre Parallel Group Study of BEC-5 Cream in Basal Cell Carcinoma,” European Academy Dermatology Venereology, Vol. 14, 2000, pp. 47-60.
  13. S. Punjabi, L. J. Cook, P. Kersey, R. Marks and R. Cerio, “Solasodine Glycoalkaloids: A Novel Topical Therapy for Basal Cell Carcinoma. A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicentre Study,” International Journal Dermatology, Vol. 47, No. 1, 2008, pp. 78-82. doi:10.1111/j.1365-4632.2007.03363.x

Source: Robert Gadimian